rich emollient used in the management of eczema, psoriasis and other dry skin conditions.


Men with advanced prostate cancer are being denied the right to take a drug which could extend their life by more than 3 months.

Although a final decision has yet to be made Abiraterone has been provisionally rejected for use by the NHS because its cost cannot be justified based on the drugs benefits.

The drug costs just under £3000 per month although it is unknown how much the NHS has been offered it for.

Prostate cancer is the most common cancer to affect men in the UK. 37,000 men are diagnosed and 10,000 die each year because of the disease.

Abiraterone not only extends life but also improves the patients quality of life by removing pain and reviving energy levels.

Do you think denying a treatment is inhumane and cruel or do you think it’s necessary to weigh up the cost with the benefits?

Read more about this story here



This is the talkhealth blog spot, where we post on a wide range of health conditions, topics, issues and concerns. We post when we see something that we believe is of interest to our visitors. Our posts do not reflect any particular view or standpoint of talkhealth, but are merely to raise attention and awareness.

Add a comment

Your email address will not be published. Required fields are marked *